Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
CABA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Cabaletta Bio, Inc.NASDAQ: CABA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $37.35M rose 28.7% year over year, behind the +44.8% change in trailing-twelve-month research & development. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at +53.7% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +28.7% toward the trailing-twelve-month pace of +44.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 142.67M USD
- Year-over-year change
- +46.8%
- 4-year CAGR
- +44.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 142.67M | +46.8% |
| FY2024 | 2024-12-31 | 97.2M | +75.4% |
| FY2023 | 2023-12-31 | 55.42M | +41.0% |
| FY2022 | 2022-12-31 | 39.3M | +20.9% |
| FY2021 | 2021-12-31 | 32.49M | — |
Research & Development vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +44.8% is the 3rd highest of 11, against a peer median of -6.0%.
- Over three fiscal years its annual growth of +53.7% compares with a peer median of +6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $159.57M USD | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $151.83M USD | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $151.01M USD | +44.8% | +53.7% | — | |
| LTM Mar 2026 | $129.09M USD | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $126.01M USD | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $92.92M USD | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $73.35M USD | -11.4% | +3.1% | 3638.2% | |
| LTM Mar 2026 | $66.19M USD | -62.3% | -19.9% | 171.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $62.33M USD | -17.5% | +9.1% | — |
| FY2025 | A$61.41M AUD | +47.8% | +25.1% | 1217.6% | |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| Peer median (excluding CABA) | — | -6.0% | +6.1% | 1217.6% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.